[Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*
D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Die Behandlung des Parkinson-Syndroms mit L-Dopa und einem Dekarboxylasehemmer (Ro 4-4602). Verlaufsbeobachtung bei 71 Patienten.